102 related articles for article (PubMed ID: 8227331)
1. A ligand-free, soluble urokinase receptor is present in the ascitic fluid from patients with ovarian cancer.
Pedersen N; Schmitt M; Rønne E; Nicoletti MI; Høyer-Hansen G; Conese M; Giavazzi R; Dano K; Kuhn W; Jänicke F
J Clin Invest; 1993 Nov; 92(5):2160-7. PubMed ID: 8227331
[TBL] [Abstract][Full Text] [Related]
2. Endogenous and Borrowed Proteolytic Activity in the
Coleman JL; Benach JL; Karzai AW
Microbiol Mol Biol Rev; 2021 May; 85(2):. PubMed ID: 33980587
[TBL] [Abstract][Full Text] [Related]
3. Roles of Factor XII in Innate Immunity.
Renné T; Stavrou EX
Front Immunol; 2019; 10():2011. PubMed ID: 31507606
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Crosstalk between the Tumor Microenvironment and Ovarian Cancer Cells: A Therapeutic Road Less Traveled.
Klymenko Y; Nephew KP
Cancers (Basel); 2018 Aug; 10(9):. PubMed ID: 30200265
[TBL] [Abstract][Full Text] [Related]
5. Negative regulation of urokinase receptor activity by a GPI-specific phospholipase C in breast cancer cells.
van Veen M; Matas-Rico E; van de Wetering K; Leyton-Puig D; Kedziora KM; De Lorenzi V; Stijf-Bultsma Y; van den Broek B; Jalink K; Sidenius N; Perrakis A; Moolenaar WH
Elife; 2017 Aug; 6():. PubMed ID: 28849762
[TBL] [Abstract][Full Text] [Related]
6. Role of urokinase receptor in tumor progression and development.
Noh H; Hong S; Huang S
Theranostics; 2013; 3(7):487-95. PubMed ID: 23843896
[TBL] [Abstract][Full Text] [Related]
7. Characterization and function of human Ly-6/uPAR molecules.
Kong HK; Park JH
BMB Rep; 2012 Nov; 45(11):595-603. PubMed ID: 23186997
[TBL] [Abstract][Full Text] [Related]
8. Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group.
Sorio C; Mafficini A; Furlan F; Barbi S; Bonora A; Brocco G; Blasi F; Talamini G; Bassi C; Scarpa A
BMC Cancer; 2011 Oct; 11():448. PubMed ID: 21999221
[TBL] [Abstract][Full Text] [Related]
9. Urokinase plasminogen activator receptor in adipose tissue macrophages of morbidly obese subjects.
Cancello R; Rouault C; Guilhem G; Bedel JF; Poitou C; Di Blasio AM; Basdevant A; Tordjman J; Clément K
Obes Facts; 2011; 4(1):17-25. PubMed ID: 21372607
[TBL] [Abstract][Full Text] [Related]
10. Challenges for drug discovery - a case study of urokinase receptor inhibition.
Chen Z; Lin L; Huai Q; Huang M
Comb Chem High Throughput Screen; 2009 Dec; 12(10):961-7. PubMed ID: 20025562
[TBL] [Abstract][Full Text] [Related]
11. Mining the ovarian cancer ascites proteome for potential ovarian cancer biomarkers.
Kuk C; Kulasingam V; Gunawardana CG; Smith CR; Batruch I; Diamandis EP
Mol Cell Proteomics; 2009 Apr; 8(4):661-9. PubMed ID: 19047685
[TBL] [Abstract][Full Text] [Related]
12. uPAR promotes formation of the p130Cas-Crk complex to activate Rac through DOCK180.
Smith HW; Marra P; Marshall CJ
J Cell Biol; 2008 Aug; 182(4):777-90. PubMed ID: 18725541
[TBL] [Abstract][Full Text] [Related]
13. Ascites induces modulation of alpha6beta1 integrin and urokinase plasminogen activator receptor expression and associated functions in ovarian carcinoma.
Ahmed N; Riley C; Oliva K; Rice G; Quinn M
Br J Cancer; 2005 Apr; 92(8):1475-85. PubMed ID: 15798771
[TBL] [Abstract][Full Text] [Related]
14. GPI-specific phospholipase D mRNA expression in tumor cells of different malignancy.
Xiaotong H; Hannocks MJ; Hampson I; Brunner G
Clin Exp Metastasis; 2002; 19(4):291-9. PubMed ID: 12090469
[TBL] [Abstract][Full Text] [Related]
15. Urokinase-catalysed cleavage of the urokinase receptor requires an intact glycolipid anchor.
Høyer-Hansen G; Pessara U; Holm A; Pass J; Weidle U; Danø K; Behrendt N
Biochem J; 2001 Sep; 358(Pt 3):673-9. PubMed ID: 11535128
[TBL] [Abstract][Full Text] [Related]
16. Upregulation of monocyte urokinase plasminogen activator receptor during human endotoxemia.
Dekkers PE; ten Hove T; te Velde AA; van Deventer SJ; van Der Poll T
Infect Immun; 2000 Apr; 68(4):2156-60. PubMed ID: 10722614
[TBL] [Abstract][Full Text] [Related]
17. Soluble urokinase receptor released from human carcinoma cells: a plasma parameter for xenograft tumour studies.
Holst-Hansen C; Hamers MJ; Johannessen BE; Brünner N; Stephens RW
Br J Cancer; 1999 Sep; 81(2):203-11. PubMed ID: 10496343
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of urokinase (uPA) and its inhibitor PAI-1 for survival in advanced ovarian carcinoma stage FIGO IIIc.
Kuhn W; Schmalfeldt B; Reuning U; Pache L; Berger U; Ulm K; Harbeck N; Späthe K; Dettmar P; Höfler H; Jänicke F; Schmitt M; Graeff H
Br J Cancer; 1999 Apr; 79(11-12):1746-51. PubMed ID: 10206287
[TBL] [Abstract][Full Text] [Related]
19. Epitope-mapped monoclonal antibodies as tools for functional and morphological analyses of the human urokinase receptor in tumor tissue.
Luther T; Magdolen V; Albrecht S; Kasper M; Riemer C; Kessler H; Graeff H; Müller M; Schmitt M
Am J Pathol; 1997 Apr; 150(4):1231-44. PubMed ID: 9094980
[TBL] [Abstract][Full Text] [Related]
20. Urokinase-type plasminogen activation in three human breast cancer cell lines correlates with their in vitro invasiveness.
Holst-Hansen C; Johannessen B; Høyer-Hansen G; Rømer J; Ellis V; Brünner N
Clin Exp Metastasis; 1996 May; 14(3):297-307. PubMed ID: 8674284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
